Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2017

Open Access 01-12-2017 | Review

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives

Authors: Lourdes Cortes-Dericks, Ralph Alexander Schmid

Published in: Respiratory Research | Issue 1/2017

Login to get access

Abstract

Malignant pleural mesothelioma (MPM) is a rare and highly drug resistant tumor arising from the mesothelial surfaces of the lung pleura. The standard method to confirm MPM is the tedious, time-consuming cytological examination of cancer biopsy. Biomarkers that are detectable in pleural effusion or patient serum are reasonable options to provide a faster and noninvasive diagnostic approach. As yet, the current biomarkers for MPM lack specificity and sensitivity to discriminate this neoplasm from other lung tumors. CD44, a multifunctional surface receptor has been implicated in tumor progression in different cancers including MPM. The interaction of CD44 with its ligand, hyaluronan (HA) has demonstrated an important role in modulating cell proliferation and invasiveness in MPM. In particular, the high expression levels of these molecules have shown diagnostic relevance in MPM. This review will summarize the biology and diagnostic implication of CD44 and HA as well as the interaction of both molecules in MPM that will demonstrate their potential as biomarkers. Augmentation of the current markers in MPM may lead to an earlier diagnosis and management of this disease.
Literature
1.
2.
3.
Fennell DA, Gaudino G, O’Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 2008;5:136–47.PubMedCrossRef
4.
5.
Ascoli V. Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines. Ann DellIstituto Super Sanità. 2015;51:52–9.
6.
Porpodis K, Zarogoulidis P, Boutsikou E, Papaioannou A, Machairiotis N, Tsakiridis K, et al. Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis. 2013;5 Suppl 4:S397–406.PubMedPubMedCentral
7.
Nasreen N, Mohammed KA, Hardwick J, Van Horn RD, Sanders K, Kathuria H, et al. Low molecular weight hyaluronan induces malignant mesothelioma cell (MMC) proliferation and haptotaxis: role of CD44 receptor in MMC proliferation and haptotaxis. Oncol Res. 2002;13:71–8.PubMed
8.
Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2015;41:27–34.PubMedCrossRef
9.
Panou V, Vyberg M, Weinreich UM, Meristoudis C, Falkmer UG, Røe OD. The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev. 2015;41:486–95.PubMedCrossRef
10.
Creaney J, Robinson BWS. Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med. 2009;15:366–70.PubMedCrossRef
11.
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.CrossRef
12.
13.
Misra S, Heldin P, Hascall VC, Karamanos NK, Skandalis SS, Markwald RR, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J. 2011;278:1429–43.PubMedPubMedCentralCrossRef
14.
15.
16.
17.
18.
Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–31.PubMedCrossRef
19.
Thapa R, Wilson GD, Thapa R, Wilson GD. The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer, The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer. Stem Cells Int. 2016;2016:e2087204.CrossRef
20.
Wang J, Li Z, White J, Zhang L. Lung cancer stem cells and implications for future therapeutics. Cell Biochem Biophys. 2014;69:389–98.PubMedCrossRef
21.
Roudi R, Madjd Z, Korourian A, Mehrazma M, Molanae S, Sabet MN, et al. Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. Cancer Biomark Sect Dis Markers. 2014;14:457–67.CrossRef
22.
Cortes-Dericks L, Froment L, Boesch R, Schmid RA, Karoubi G. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH (high) CD44 (+) phenotype and sphere-forming capacity. BMC Cancer. 2014;14:304.PubMedPubMedCentralCrossRef
23.
Alamgeer M, Peacock CD, Matsui W, Ganju V, Watkins DN. Cancer stem cells in lung cancer: Evidence and controversies. Respirol Carlton Vic. 2013;18:757–64.CrossRef
24.
Leung EL-H, Fiscus RR, Tung JW, Tin VP-C, Cheng LC, Sihoe AD-L, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 2010;5:e14062.PubMedPubMedCentralCrossRef
25.
Eramo A, Haas TL, De Maria R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene. 2010;29:4625–35.PubMedCrossRef
26.
Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med. 2015;4:1033–43.PubMedPubMedCentralCrossRef
27.
28.
Knudson W. The role of CD44 as a cell surface hyaluronan receptor during tumor invasion of connective tissue. Front Biosci J Virtual Libr. 1998;3:d604–615.CrossRef
29.
30.
Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: An overview. Immunol Cell Biol. 1996;74:A1–7.PubMedCrossRef
31.
Fujimoto N, Gemba K, Asano M, Fuchimoto Y, Wada S, Ono K, et al. Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma. Respir Investig. 2013;51:92–7.PubMedCrossRef
32.
Martensson G, Thylen A, Lindquist U, Hjerpe A. The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods. Cancer. 1994;73:1406–10.PubMedCrossRef
33.
Pettersson T, Fröseth B, Riska H, Klockars M. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest. 1988;94:1037–9.PubMedCrossRef
34.
Frebourg T, Lerebours G, Delpech B, Benhamou D, Bertrand P, Maingonnat C, et al. Serum hyaluronate in malignant pleural mesothelioma. Cancer. 1987;59:2104–7.PubMedCrossRef
35.
Dahl IM, Solheim OP, Erikstein B, Müller E. A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease. Cancer. 1989;64:68–73.PubMedCrossRef
36.
Arai H, Kang KY, Sato H, Satoh K, Nagai H, Motomiya M, et al. Significance of the quantification and demonstration of hyaluronic acid in tissue specimens for the diagnosis of pleural mesothelioma. Am Rev Respir Dis. 1979;120:529–32.PubMed
37.
Arai H. A study on acid glycosaminoglycans in pleural diseases. Sci Rep Res Inst Tohoku Univ Med. 1979;26:46–70.PubMed
38.
Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci. 2002;39:527–79.PubMedCrossRef
39.
Mackay CR, Terpe HJ, Stauder R, Marston WL, Stark H, Günthert U. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol. 1994;124:71–82.PubMedCrossRef
40.
41.
Karousou E, Misra S, Ghatak S, Dobra K, Götte M, Vigetti D, et al. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer. Matrix Biol. 2017;59:3-22.
42.
Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Front Immunol. 2015;6. doi:10.​3389/​fimmu.​2015.​00201
43.
44.
Tran TA, Kallakury BV, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol. 1997;28:809–14.PubMedCrossRef
45.
Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, et al. Trametinib plus 4-methylumbelliferone exhibits antitumor effects by ERK blockade and CD44 downregulation and affects PD-1 and PD-L1 in malignant pleural mesothelioma. J Thorac Oncol. 2017;12:477–90.PubMedCrossRef
46.
Nuvoli B, Germoni S, Morosetti C, Santoro R, Cortese G, Masi S, et al. Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease. Mol Cancer. 2014;13:69.PubMedPubMedCentralCrossRef
47.
Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis. Cancer Lett. 2017;385:215–24.PubMedCrossRef
48.
Bourguignon LY, Zhu H, Shao L, Chen YW. CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration. J Biol Chem. 2000;275:1829–38.PubMedCrossRef
49.
Bourguignon LY, Zhu D, Zhu H. CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci. 1998;3:d637–649.PubMedCrossRef
50.
Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.PubMedCrossRef
51.
Bourguignon LYW, Singleton PA, Zhu H, Zhou B. Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells. J Biol Chem. 2002;277:39703–12.PubMedCrossRef
52.
Okamoto I, Kawano Y, Tsuiki H, Sasaki J, Nakao M, Matsumoto M, et al. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. Oncogene. 1999;18:1435–46.PubMedCrossRef
53.
Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, Emlet DR, Holgado-Madruga M, et al. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol. 2002;160:441–7.PubMedPubMedCentralCrossRef
54.
Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem. 2006;281:5861–8.PubMedCrossRef
55.
Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, et al. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res. 1994;54:4539–46.PubMed
56.
Chew SH, Okazaki Y, Akatsuka S, Wang S, Jiang L, Ohara Y, et al. Rheostatic CD44 isoform expression and its association with oxidative stress in human malignant mesothelioma. Free Radic Biol Med. 2017;106:91–9.PubMedCrossRef
57.
58.
Thorne RF, Legg JW, Isacke CM. The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events. J Cell Sci. 2004;117(Pt 3):373–80.PubMed
59.
60.
Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a review. Veterinari Medicina. 2008;8:397–411.
61.
Hill A, McFarlane S, Johnston PG, Waugh DJJ. The emerging role of CD44 in regulating skeletal micrometastasis. Cancer Lett. 2006;237:1–9.PubMedCrossRef
62.
63.
Chanmee T, Ontong P, Kimata K, Itano N. Key roles of hyaluronan and its CD44 receptor in the stemness and survival of cancer stem cells. Front Oncol. 2015;5:180.PubMedPubMedCentralCrossRef
64.
Geramizadeh B, Janfeshan K, Saberfiroozi M. Serum hyaluronic acid as a noninvasive marker of hepatic fibrosis in chronic hepatitis B. Saudi J Gastroenterol. 2008;14:174–7.PubMedPubMedCentralCrossRef
65.
Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol. 2005;4:6.PubMedPubMedCentralCrossRef
66.
Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat. 1998;5:187–92.PubMedCrossRef
67.
Bourguignon LYW. Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin Cancer Biol. 2008;18:251–9.PubMedPubMedCentralCrossRef
68.
Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528–39.PubMedCrossRef
69.
Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol. 2007;23:435–61.PubMedCrossRef
70.
Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33–45.PubMedCrossRef
71.
Turley EA, Noble PW, Bourguignon LYW. Signaling properties of hyaluronan receptors. J Biol Chem. 2002;277:4589–92.PubMedCrossRef
72.
Bourguignon LYW. Hyaluronan-CD44 interaction promotes microRNA signaling and RhoGTPase activation leading to tumor progression. Small GTPases. 2012;3:53–9.PubMedPubMedCentralCrossRef
73.
Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46:1271–7.PubMedCrossRef
74.
Hanagiri T, Shinohara S, Takenaka M, Shigematsu Y, Yasuda M, Shimokawa H, et al. Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma. Tumour Biol. 2012;33:2135–41.PubMedCrossRef
75.
Asplund T, Heldin P. Hyaluronan receptors Are expressed on human malignant mesothelioma cells but not on normal mesothelial cells. Cancer Res. 1994;54:4516–23.PubMed
76.
Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, Ardissone F, et al. Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol. 2008;130:58–64.PubMedCrossRef
77.
Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055–61.PubMedPubMedCentralCrossRef
78.
Tajima K, Ohashi R, Sekido Y, Hida T, Nara T, Hashimoto M, et al. Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 2010;29:1941–51.PubMedCrossRef
79.
Penno MB, Askin FB, Ma H, Carbone M, Vargas MP, Pass HI. High CD44 expression on human mesotheliomas mediates association with hyaluronan. Cancer J Sci Am. 1995;1:196–203.PubMed
80.
Attanoos RL, Webb R, Gibbs AR. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Histopathology. 1997;30:260–3.PubMedCrossRef
81.
Afify AM, Stern R, Michael CW. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol. 2005;32:145–50.PubMedCrossRef
82.
Alì G, Borrelli N, Riccardo G, Proietti A, Pelliccioni S, Niccoli C, et al. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia. J Thorac Oncol. 2013;8:1389–95.PubMedCrossRef
83.
Törrönen K, Soini Y, Pääkkö P, Parkkinen J, Sironen R, Rilla K. Mesotheliomas show higher hyaluronan positivity around tumor cells than metastatic pulmonary adenocarcinomas. Histol Histopathol. 2016;31:1113–22.PubMed
84.
Porcel JM, Esquerda A, Rodriguez-Panadero F, Martínez-Iribarren A, Bielsa S. The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies. J Thorac Oncol. 2011;6:190–4.PubMedCrossRef
85.
Meyer K, Chaffee E. Hyaluronic acid in the pleural fluid associated with a malignant tumor involving the pleura and peritoneum. J Biol Chem. 1940;133:83–91.
86.
Roboz J, Greaves J, Silides D, Chahinian AP, Holland JF. Hyaluronic acid content of effusions as a diagnostic Aid for malignant mesothelioma. Cancer Res. 1985;45:1850–4.PubMed
87.
Chiu B, Churg A, Tengblad A, Pearce R, McCaughey WTE. Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer. 1984;54:2195–9.PubMedCrossRef
88.
Thylén A, Wallin J, Martensson G. Hyaluronan in serum as an indicator of progressive disease in hyaluronan-producing malignant mesothelioma. Cancer. 1999;86:2000–5.PubMedCrossRef
89.
Klominek J, Robért K-H, Hjerpe A, Wickström B, Gahrton G. Serum-dependent growth patterns of Two, newly established human mesothelioma cell lines. Cancer Res. 1989;49:6118–22.PubMed
90.
Azumi N, Underhill CB, Kagan E, Sheibani K. A novel biotinylated probe specific for hyaluronate. Its diagnostic value in diffuse malignant mesothelioma. Am J Surg Pathol. 1992;16:116–21.PubMedCrossRef
91.
Boersma A, Degand P, Biserte G, Havez R. Report on the study of hyaluronic acid in the diagnosis of pleural mesotheliomas: study of 100 hyaluronic acid rich effusions. Biomedicine. 1975;22:428–32.PubMed
92.
Atagi S, Ogawara M, Kawahara M, Sakatani M, Furuse K, Ueda E, et al. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn J Clin Oncol. 1997;27:293–7.PubMedCrossRef
93.
Matzel W, Schubert G. Hyaluronic acid in pleural fluids: an additional parameter for clinical diagnosis on diffuse mesotheliomas (author’s transl). Arch Geschwulstforsch. 1979;49:146–54.PubMed
94.
Waxler B, Eisenstein R, Battifora H. Electrophoresis of tissue glycosaminoglycans as an aid in the diagnosis of mesotheliomas. Cancer. 1979;44:221–7.PubMedCrossRef
95.
Kawai T, Suzuki M, Shinmei M, Maenaka Y, Kageyama K. Glycosaminoglycans in malignant diffuse mesothelioma. Cancer. 1985;56:567–74.PubMedCrossRef
96.
Nakano T, Fujii J, Tamura S, Amuro Y, Nabeshima K, Horai T, et al. Glycosaminoglycan in malignant pleural mesothelioma. Cancer. 1986;57:106–10.PubMedCrossRef
97.
Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA. Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 2007;450:455–61.PubMedCrossRef
98.
Hillerdal G, Lindqvist U, Engström-Laurent A. Hyaluronan in pleural effusions and in serum. Cancer. 1991;67:2410–4.PubMedCrossRef
99.
Teder P, Versnel MA, Heldin P. Stimulatory effects of pleural fluids from mesothelioma patients on CD44 expression, hyaluronan production and cell proliferation in primary cultures of normal mesothelial and transformed cells. Int J Cancer. 1996;67:393–8.PubMedCrossRef
100.
101.
Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11:254–67.PubMedCrossRef
102.
Williams K, Motiani K, Giridhar PV, Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre) metastatic niches. Exp Biol Med. 2013;238:324–38.CrossRef
103.
Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, et al. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One. 2013;8:e57020.PubMedPubMedCentralCrossRef
104.
Frei C, Opitz I, Soltermann A, Fischer B, Moura U, Rehrauer H, et al. Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis. 2011;32:1324–32.PubMedCrossRef
105.
Ghani FI, Yamazaki H, Iwata S, Okamoto T, Aoe K, Okabe K, et al. Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun. 2011;404:735–42.PubMedCrossRef
106.
Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed. Int J Oncol. 2010;37:437–44.PubMed
107.
108.
van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BAJM, Moons KGM. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer. 2011;104:1325–33.PubMedPubMedCentralCrossRef
109.
Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111:106–9.PubMedCrossRef
110.
Fletcher SV, Clark RJ. The Portsmouth thoracoscopy experience, an evaluation of service by retrospective case note analysis. Respir Med. 2007;101:1021–5.PubMedCrossRef
111.
Fassina A, Fedeli U, Corradin M, Da Frè M, Fabbris L. Accuracy and reproducibility of pleural effusion cytology. Leg Med. 2008;10:20–5.CrossRef
112.
113.
114.
Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet Lond Engl. 2003;362:1612–6.CrossRef
115.
Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, et al. Sensitive and specific New enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res. 2008;14:1431–7.PubMedCrossRef
116.
Pantazopoulos I, Boura P, Xanthos T, Syrigos K. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J. 2013;41:706–15.PubMedCrossRef
117.
Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol. 2008;3:851–7.PubMedCrossRef
118.
Greillier L, Baas P, Welch JJ, Hasan B, Passioukov A. Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther. 2008;12:375–90.PubMedCrossRef
119.
120.
Kojima T, Oh-eda M, Hattori K, Taniguchi Y, Tamura M, Ochi N, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem. 1995;270:21984–90.PubMedCrossRef
121.
Grigoriu BD, Grigoriu C, Chahine B, Gey T, Scherpereel A. Clinical utility of diagnostic markers for malignant pleural mesothelioma. Monaldi Arch Chest Dis. 2009;71:31–8.PubMed
122.
123.
Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med. 2012;367:1417–27.PubMedPubMedCentralCrossRef
124.
Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax. 2014;69:895–902.PubMedPubMedCentralCrossRef
125.
Creaney J, Dick IM, Segal A, Musk AW, Robinson BWS. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Lung Cancer. 2013;82:491–8.PubMedCrossRef
126.
Creaney J, Robinson BWS. Malignant mesothelioma biomarkers - from discovery to use in clinical practise for diagnosis, monitoring, screening and treatment. Chest. 2016; pii: S0012-3692(16)62593-X .DOI:10.​1016/​j.​chest.​2016.​12.​004.
127.
Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, et al. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Cancer Invest. 2013;31:43–50.PubMedCrossRef
128.
Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol. 2012;30:1541–9.PubMedPubMedCentralCrossRef
129.
Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin M-C, et al. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem. 2009;42:1046–50.PubMedCrossRef
130.
Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest. 2007;132:1239–46.PubMedCrossRef
131.
van den Heuvel MM, Korse CM, Bonfrer JMG, Baas P. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer. 2008;59:350–4.PubMedCrossRef
132.
Muley T, Dienemann H, Herth FJF, Thomas M, Meister M, Schneider J. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer. J Thorac Oncol. 2013;8:947–51.PubMedCrossRef
133.
Grigoriu B-D, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res. 2007;13:2928–35.PubMedCrossRef
134.
Bayram M, Dongel I, Akbaş A, Benli İ, Akkoyunlu ME, Bakan ND. Serum Biomarkers in Patients with Mesothelioma and Pleural Plaques and Healthy Subjects Exposed to Naturally Occurring Asbestos. Lung. 2014;192:197–203.PubMedCrossRef
135.
Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136:888–96.PubMedCrossRef
136.
Pass HI, Liu Z, Wali A, Bueno R, Land S, Lott D, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res. 2004;10:849–59.PubMedCrossRef
137.
Holloway AJ, Diyagama DS, Opeskin K, Creaney J, Robinson BWS, Lake RA, et al. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res. 2006;12:5129–35.PubMedCrossRef
138.
Gordon GJ. Transcriptional profiling of mesothelioma using microarrays. Lung Cancer. 2005;49 Suppl 1:S99–103.PubMedCrossRef
139.
Panadero FR. Diagnosis and Treatment of Malignant Pleural Mesothelioma. Arch Bronconeumol Engl Ed. 2015;51:177–84.CrossRef
140.
Stahel RA, Weder W, Lievens Y, Felip E. On behalf of the ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Supplement 5):v126–8.PubMedCrossRef
Metadata
Title
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives
Authors
Lourdes Cortes-Dericks
Ralph Alexander Schmid
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2017
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-017-0546-5

Other articles of this Issue 1/2017

Respiratory Research 1/2017 Go to the issue

Research

Multiple biomarkers predict disease severity, progression and mortality in COPD

Research

Outcomes after early and delayed rehabilitation for exacerbation of chronic obstructive pulmonary disease: a nationwide retrospective cohort study in Japan

Letter to the Editor

Asthma-COPD overlap is not a homogeneous disorder: further supporting data

Research

A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease

Commentary

Eligibility of real-life patients with COPD for inclusion in RCTs: a commentary

Research

Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits